Transitioning Isotopes
for Prostate Brachytherapy
“The biggest concern was initially rectal dose,” Dr. Taylor said. “We realized that was not as big of a concern as originally thought. Dosimetry aspects were alleviated by seeing the planning in live time. Talking to a physician who had done several hundred implants with Cesium, he was seeing less urinary symptoms in his clinic. It confirmed someone treating patients consistently with Cesium were seeing benefits.”
Are you considering switching to Cesium-131?
In 2018, Dr. Bernard Taylor made the switch to Cesium as his isotope of choice for prostate brachytherapy. In this 30 minute webinar, he shared his experience including early concerns, elements critical to his successful, smooth transition.
What about logistics? What about dosimeter time frames and constraints? How have the early results and patient-reported outcomes compared to Iodine and Palladium?
Dr. Taylor was joined by Atef Omari, medical physicist with Bon Secours Health System.
After nearly 10 years and more than 18,000 patients treated following its FDA approval for prostate cancer treatment, sufficient scientific data and patient-reported evidence suggest that Cesium-131 delivers equivalent to, or superior outcomes compared to Iodine and Palladium for both monotherapy and combination therapy.
These results, including quick returns to baseline values and fast resolution of acute side effects, can be attributed to Cesium-131’s combination of high energy and short half-life effectively delivering a high dose of radiation more quickly for high-risk patients in a low dose rate setting.
If you would like to know how easy it is to introduce Cesium-131 in your practice schedule a consultation with our sales team below.
Learn More About Transitioning to Cesium-131
Sales and Marketing
E: salesops@isoray.flywheelstaging.com